Pharmaceuticals, Free Full-Text
4.7 (682) · $ 16.50 · In stock
Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has not developed BBB drug delivery technology, which would enable industry to invent new therapeutics for AD that actually penetrate into brain parenchyma from blood. In 2020, less than 1% of all AD drug development projects use a BBB drug delivery technology. The pathogenesis of AD involves chronic neuro-inflammation, the progressive deposition of insoluble amyloid-beta or tau aggregates, and neural degeneration. New drugs that both attack these multiple sites in AD, and that have been coupled with BBB drug delivery technology, can lead to new and effective treatments of this serious disorder.
Pharmaceuticals Free Full-Text Effects Of, 56% OFF
Pharmacy - Wikipedia
Pharmaceuticals, Free Full-Text
Synthesis of biochar from iron-free and iron-containing microalgal biomass for the removal of pharmaceuticals from water - ScienceDirect
Current Pharmaceutical Design
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Pharmaceuticals, Free Full-Text, foto do pou sigma
Pharmaceuticals, Free Full-Text
Pharmaceuticals, Free Full-Text
Buy OZONE Ozone Signature Leave In Hair Serum 30 ML
